Moomoo AIのまとめ
SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
医薬品会社のSciSparc Ltd.は、2023年12月31日に終了した会計年度の年間財務パフォーマンスを発表しました。カンナビノイドベースの治療薬の開発に特化した同社は、薬剤開発部門からの収益を上げていませんが、ヘンプ製品のオンライン販売で2,879,000ドルの収益を報告しました。売上原価（cogs）は683,000ドルで、粗利益は2,196,000ドルでした。研究開発費は1,641,000ドル、一般管理費は5,031,000ドルでした。また、無形資産の減損額は1,042,000ドルを記録しました。SciSparcは、当年の純損失が5,883,000ドルで、株式当たりの基本的および希薄化...すべて展開
医薬品会社のSciSparc Ltd.は、2023年12月31日に終了した会計年度の年間財務パフォーマンスを発表しました。カンナビノイドベースの治療薬の開発に特化した同社は、薬剤開発部門からの収益を上げていませんが、ヘンプ製品のオンライン販売で2,879,000ドルの収益を報告しました。売上原価（cogs）は683,000ドルで、粗利益は2,196,000ドルでした。研究開発費は1,641,000ドル、一般管理費は5,031,000ドルでした。また、無形資産の減損額は1,042,000ドルを記録しました。SciSparcは、当年の純損失が5,883,000ドルで、株式当たりの基本的および希薄化後の損失は14.43ドルでした。同社の共同出資投資からの損失は210,000ドルでした。主に金融負債の公正価値の変化からの金融収入は2,219,000ドルであり、金融資産への投資の重新計測からの損失を含む金融費用は1,055,000ドルでした。同社の将来の計画には、薬剤の開発努力を継続し、ヘンプベースの製品のオンライン販売を拡大することが含まれます。
役に立った
役に立たない